Bindley Western Announces a Multi-Year PharmaceuticalContract With Winn-Dixie.

Business & Health Editors

INDIANAPOLIS--(BW HealthWire)--Sept. 19, 2000

Bindley Western Industries, Inc. (NYSE:BDY) announced today that its wholesale drug division, Bindley Western Drug Company, has signed a multi-year supply agreement with Winn-Dixie Stores.

While

Bindley Western has been a long-term supplier to Winn-Dixie, this contract will expand the business relationship. Winn-Dixie will convert to Bindley Western's Generic Advantage Program (GAP) and both companies intend to work very closely together to maximize the performance of Winn-Dixie's pharmacy assets and dispensing facilities.

"This agreement exemplifies the success Bindley Western is creating through the development of partnership relationships with our customers. We have served Winn-Dixie for more than a decade and both companies have successfully helped one another grow. Serving as the primary supplier to Winn-Dixie's 700 pharmacies, and identifying and implementing cost-saving efficiencies for their operations will help to strengthen this bond," stated Keith Burks, President of Bindley Western Drug Company.

Indianapolis-based Bindley Western, with annualized revenues of $10 billion, is a Fortune 500 company that provides a synergistic array of cost effective pharmaceutical and supply channel management products and services from 17 distribution facilities located in 14 states and from 32 specialty pharmacies located in 15 states. Customers include chain drug stores, independent drug stores, supermarkets and mass retailers with their own pharmacies, hospitals, clinics, HMOs, and managed care organizations, all of which are dedicated to lowering the cost of healthcare and improving the quality of patient care. Information on Bindley Western is available on-line at www.bindley.com. Information on Central Pharmacy Services is available on-line at www.centralpharmacy.com.

Certain information in this press release contains forward-looking statements as defined in Section 27A of the Securities Act and 21E of the Exchange Act. Certain factors could cause actual results to differ materially from those in the forward-looking statements. The most significant of such uncertainties are described in the company's Forms 10-K, 10-Q and 8-K and in exhibits to those reports.